{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:23:10Z","timestamp":1794547390986,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04402-w","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:02:09Z","timestamp":1778835729000},"page":"2522-2532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7783-2495","authenticated-orcid":false,"given":"Cyril","family":"Erameh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Okwaraeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-4938","authenticated-orcid":false,"given":"Christine","family":"Kleist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osahogie","family":"Edeawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Adedosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1718-1885","authenticated-orcid":false,"given":"Enomen","family":"Ekata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9088-9197","authenticated-orcid":false,"given":"Chukwuyem","family":"Abejegah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampson","family":"Owhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-0259","authenticated-orcid":false,"given":"Femi","family":"Babatunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Omansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6123-7960","authenticated-orcid":false,"given":"Augusto","family":"Meneguim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7139-2687","authenticated-orcid":false,"given":"Alexandre","family":"Duvignaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Mischlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndapewa","family":"Ithete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Oestereich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hinzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liasu","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1239-4372","authenticated-orcid":false,"given":"Sophie","family":"Duraffour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Eifedyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-8316","authenticated-orcid":false,"given":"Sylvanus","family":"Okogbenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Akhideno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladele Oluwafemi","family":"Ayodeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0230","authenticated-orcid":false,"given":"Stephan","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G.","family":"Wicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jaspard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Pahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-1885","authenticated-orcid":false,"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7375-3685","authenticated-orcid":false,"given":"Mirjam","family":"Groger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"4402_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2214-109X(20)30518-0","volume":"9","author":"A Duvignaud","year":"2021","unstructured":"Duvignaud, A. et al. Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study. Lancet Glob. Health 9, 469\u2013478 (2021).","journal-title":"Lancet Glob. Health"},{"key":"4402_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.185.4147.263","volume":"185","author":"TP Monath","year":"1974","unstructured":"Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from mastomys natalensis rodents during an epidemic in sierra leone. Science. 185, 263\u2013265 (1974).","journal-title":"Science."},{"key":"4402_CR3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.idc.2019.08.002","volume":"33","author":"DA Asogun","year":"2019","unstructured":"Asogun, D. A., G\u00fcnther, S., Akpede, G. O., Ihekweazu, C. & Zumla, A. Lassa fever: epidemiology, clinical features, diagnosis, management and prevention. Infect. Dis. Clin. North Am. 33, 933\u2013951 (2019).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"4402_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","volume":"311","author":"SP Fisher-Hoch","year":"1995","unstructured":"Fisher-Hoch, S. P. et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. Br. Med. J. 311, 857\u2013859 (1995).","journal-title":"Br. Med. J."},{"key":"4402_CR5","volume":"8","author":"JA Grace","year":"2021","unstructured":"Grace, J. A., Egoh, I. J. & Udensi, N. Epidemiological trends of Lassa fever in Nigeria from 2015-2021: a review. Ther. Adv. Infect. Dis. 8, 20499361211058252 (2021).","journal-title":"Ther. Adv. Infect. Dis."},{"key":"4402_CR6","unstructured":"Nigeria Centre for Disease Control and Prevention. Lassa Fever Situation Report. 2024."},{"key":"4402_CR7","unstructured":"World Health Organization. A research and development Blueprint for action to prevent epidemics. 2018."},{"key":"4402_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(24)00229-9","volume":"24","author":"KA Moore","year":"2024","unstructured":"Moore, K. A. et al. Lassa fever research priorities: towards effective medical countermeasures by the end of the decade. Lancet Infect. Dis. 24, 696\u2013706 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"4402_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa2501073","volume":"393","author":"E Malkin","year":"2025","unstructured":"Malkin, E. et al. rVSV\u0394G-LASV-GPC Study Group. Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate. N. Engl. J. Med. 393, 1807\u20131818 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4402_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","volume":"87","author":"KA Eberhardt","year":"2019","unstructured":"Eberhardt, K. A. et al. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int. J. Infect. Dis. 87, 15\u201320 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"4402_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/cid\/ciac578","volume":"76","author":"M Groger","year":"2023","unstructured":"Groger, M. et al. Pharmacokinetics of ribavirin in the treatment of lassa fever: an observational clinical study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Clin. Infect. Dis. 76, 841\u2013848 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"4402_CR12","doi-asserted-by":"publisher","first-page":"e0010289","DOI":"10.1371\/journal.pntd.0010289","volume":"16","author":"AP Salam","year":"2022","unstructured":"Salam, A. P. et al. Ribavirin for treating Lassa fever: a systematic review of pre-clinical studies and implications for human dosing. PLoS Negl. Trop. Dis. 16, e0010289 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"4402_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00951-22","volume":"66","author":"SM Amberg","year":"2022","unstructured":"Amberg, S. M. et al. Safety and pharmacokinetics of LHF-535, a potential treatment for lassa fever, in healthy adults. Antimicrob. Agents Chemother. 66, e0095122 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4402_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105125","volume":"193","author":"BB Gowen","year":"2021","unstructured":"Gowen, B. B. et al. Potent inhibition of arenavirus infection by a novel fusion inhibitor. Antiviral Res. 193, 105125 (2021).","journal-title":"Antiviral Res."},{"key":"4402_CR15","unstructured":"A study to assess the safety, tolerability, and pharmacokinetics of oral ARN-75039 in healthy adult subjects 2025. Arisan Therapeutics https:\/\/clinicaltrials.gov\/study\/NCT05735249 (2025)."},{"key":"4402_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","volume":"21","author":"BM Warner","year":"2024","unstructured":"Warner, B. M., Safronetz, D. & Stein, D. R. Current perspectives on vaccines and therapeutics for Lassa Fever. Virol. J. 21, 320 (2024).","journal-title":"Virol. J."},{"key":"4402_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7034","volume":"16","author":"SR Welch","year":"2024","unstructured":"Welch, S. R. et al. Delayed low-dose oral administration of 4\u2032-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease. Sci. Transl. Med. 16, eado7034 (2024).","journal-title":"Sci. Transl. Med."},{"key":"4402_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","volume":"21","author":"RF Garry","year":"2023","unstructured":"Garry, R. F. Lassa fever\u2014the road ahead. Nat. Rev. Microbiol. 21, 87\u201396 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"4402_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn Acad. Ser. B 93, 449\u2013463 (2017).","journal-title":"Proc. Jpn Acad. Ser. B"},{"key":"4402_CR20","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","volume":"226","author":"FG Hayden","year":"2022","unstructured":"Hayden, F. G. et al. Favipiravir treatment of uncomplicated influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials. J. Infect. Dis. 226, 1790\u20131799 (2022).","journal-title":"J. Infect. Dis."},{"key":"4402_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967","volume":"13","author":"D Sissoko","year":"2016","unstructured":"Sissoko, D. et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 13, e1001967 (2016).","journal-title":"PLoS Med."},{"key":"4402_CR22","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s40121-021-00517-4","volume":"10","author":"M Shinkai","year":"2021","unstructured":"Shinkai, M. et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infect. Dis. Ther. 10, 2489\u20132509 (2021).","journal-title":"Infect. Dis. Ther."},{"key":"4402_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep14775","volume":"5","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).","journal-title":"Sci. Rep."},{"key":"4402_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/infdis\/jiv522","volume":"213","author":"L Oestereich","year":"2016","unstructured":"Oestereich, L. et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J. Infect. Dis. 213, 934\u2013938 (2016).","journal-title":"J. Infect. Dis."},{"key":"4402_CR25","doi-asserted-by":"publisher","first-page":"e1008535","DOI":"10.1371\/journal.pcbi.1008535","volume":"17","author":"G Lingas","year":"2021","unstructured":"Lingas, G., Rosenke, K., Safronetz, D. & Guedj, J. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PLoS Comput. Biol. 17, e1008535 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"4402_CR26","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3201\/eid2409.180233","volume":"24","author":"K Rosenke","year":"2018","unstructured":"Rosenke, K. et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg. Infect. Dis. 24, 1696\u20131699 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"4402_CR27","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/cid\/cix406","volume":"65","author":"VN Raabe","year":"2017","unstructured":"Raabe, V. N. et al. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin. Infect. Dis. 65, 855\u2013859 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"4402_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. et al. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314, 20\u201326 (1986).","journal-title":"N. Engl. J. Med."},{"key":"4402_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/psp4.12685","volume":"10","author":"K Irie","year":"2021","unstructured":"Irie, K. et al. Population pharmacokinetics of favipiravir in patients with COVID-19. CPT Pharmacometrics Syst. Pharmacol. 10, 1161\u20131170 (2021).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"4402_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/cpt.1844","volume":"108","author":"YX Du","year":"2020","unstructured":"Du, Y. X. & Chen, X. P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. 108, 242\u2013247 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4402_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1592\/phco.27.4.494","volume":"27","author":"MP Muller","year":"2007","unstructured":"Muller, M. P. et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy 27, 494\u2013503 (2007).","journal-title":"Pharmacotherapy"},{"key":"4402_CR32","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.2147\/IDR.S287934","volume":"13","author":"RJ Kaur","year":"2020","unstructured":"Kaur, R. J. et al. Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Infect. Drug. Resist. 13, 4427\u20134438 (2020).","journal-title":"Infect. Drug. Resist."},{"key":"4402_CR33","doi-asserted-by":"publisher","unstructured":"Rowland, T. et al. Optimal dose and safety of intravenous favipiravir in hospitalised patients with COVID-19: a dose-escalating, randomized controlled phase Ib study. Clin. Pharmacol. Ther. https:\/\/doi.org\/10.1002\/cpt.70261 (2026).","DOI":"10.1002\/cpt.70261"},{"key":"4402_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102858","volume":"18","author":"C Erameh","year":"2025","unstructured":"Erameh, C. et al. Electrocardiographic alterations in patients treated for acute Lassa fever: description of results from a phase II clinical trial in Nigeria. J. Infect. Public Health. 18, 102858 (2025).","journal-title":"J. Infect. Public Health."},{"key":"4402_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jacc.2018.10.043","volume":"74","author":"FM Kusumoto","year":"2019","unstructured":"Kusumoto, F. M. et al. 2018 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J. Am. Coll. Cardiol. 74, 932\u2013987 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4402_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.5455\/annalsmedres.2021.09.564","volume":"29","author":"S Karadavut","year":"2022","unstructured":"Karadavut, S. & Altintop, I. Distribution of arrhythmic events in COVID-19 patients receiving favipiravir and hydroxychloroquine. Ann. Med. Res. 29, 519\u2013524 (2022).","journal-title":"Ann. Med. Res."},{"key":"4402_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.toxlet.2022.09.011","volume":"371","author":"A Gunaydin-Akyildiz","year":"2022","unstructured":"Gunaydin-Akyildiz, A., Aksoy, N., Boran, T., Ilhan, E. N. & Ozhan, G. Favipiravir induces oxidative stress and genotoxicity in cardiac and skin cells. Toxicol. Lett. 371, 9\u201316 (2022).","journal-title":"Toxicol. Lett."},{"key":"4402_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijid.2022.04.035","volume":"120","author":"DT Hung","year":"2022","unstructured":"Hung, D. T. et al. The efficacy and adverse effects of favipiravir on patients with COVID-19: a systematic review and meta-analysis of published clinical trials and observational studies. Int. J. Infect. Dis. 120, 217\u2013227 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"4402_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.4269\/ajtmh.1986.35.401","volume":"35","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am. J. Trop. Med. Hyg. 35, 401\u2013407 (1986).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"4402_CR40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1473-3099(20)30737-4","volume":"21","author":"J Strampe","year":"2021","unstructured":"Strampe, J. et al. Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study. Lancet Infect. Dis. 21, 876\u2013886 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"4402_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae575","volume":"11","author":"E Ogbaini-Emovon","year":"2024","unstructured":"Ogbaini-Emovon, E. et al. Virus load kinetics in Lassa fever patients treated with ribavirin: a retrospective cohort study from southern Nigeria. Open Forum Infect. Dis. 11, ofae575 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"4402_CR42","unstructured":"Pharmacokinetics, tolerability and safety of favipiravir compared to ribavirin for the treatment of Lassa Fever (SAFARI). ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04907682?term=NCT04907682&rank=1 (2023)."},{"key":"4402_CR43","unstructured":"National Guideline for Lassa Fever Case Management (Nigeria Centre for Disease Control, 2018)."},{"key":"4402_CR44","doi-asserted-by":"publisher","first-page":"e036936","DOI":"10.1136\/bmjopen-2020-036936","volume":"10","author":"C Erameh","year":"2020","unstructured":"Erameh, C. et al. Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. BMJ Open. 10, e036936 (2020).","journal-title":"BMJ Open."},{"key":"4402_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1208\/s12248-012-9368-z","volume":"14","author":"R Jin","year":"2012","unstructured":"Jin, R., Fossler, M. J., McHutchison, J. G., Howell, C. D. & Dowling, T. C. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J. 14, 571\u2013580 (2012).","journal-title":"AAPS J."},{"key":"4402_CR46","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/jac\/dkab135","volume":"76","author":"H Pertinez","year":"2021","unstructured":"Pertinez, H., Rajoli, R. K. R., Khoo, S. H. & Owen, A. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5\u2032-triphosphate exposure to support posology for SARS-CoV-2. J. Antimicrob. Chemother. 76, 2121\u20132128 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"4402_CR47","doi-asserted-by":"publisher","first-page":"103125","DOI":"10.1016\/j.ebiom.2020.103125","volume":"62","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. eBioMedicine. 62, 103125 (2020).","journal-title":"eBioMedicine."},{"key":"4402_CR48","first-page":"650","volume":"8","author":"MM McCarron","year":"1974","unstructured":"McCarron, M. M. & Devine, B. J. Clinical pharmacy: case studies: case number 25 gentamicin therapy. Drug Intell. Clin. Pharm. 8, 650\u2013655 (1974).","journal-title":"Drug Intell. Clin. Pharm."},{"key":"4402_CR49","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S2666-5247(21)00178-6","volume":"3","author":"A Thielebein","year":"2022","unstructured":"Thielebein, A. et al. Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study. Lancet Microbe 3, e32\u2013e40 (2022).","journal-title":"Lancet Microbe"},{"key":"4402_CR50","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand, M. & Karlsson, M. O. Handling data below the limit of quantification in mixed effect models. AAPS J. 11, 371\u2013380 (2009).","journal-title":"AAPS J."},{"key":"4402_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal, S. L. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28, 481\u2013504 (2001).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"4402_CR52","unstructured":"Report on the Deliberation Results\u2014Avigan Tablet 200\u2009mg. Japan (Evaluation and Licensing Division\u2014Pharmaceutical and Food Safety Bureau, 2014)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04402-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:08Z","timestamp":1784210528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04402-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4402"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04402-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}